Prevention of the First Episode of Psychosis

Psychiatric Clinics of North America

Volumn 34, Issue 1, 2011, Pages 95-107

  McFarlane, William R ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Maine Medical Center Research Institute   (United States)

Author keywords

High risk; Mood disorder; Prevention; Prodromal; Psychosis; Schizophrenia

Indexed keywords

OLANZAPINE; OMEGA 3 FATTY ACID; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

COGNITIVE THERAPY; EARLY DIAGNOSIS; EDUCATION PROGRAM; FAMILY THERAPY; HELP SEEKING BEHAVIOR; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; PATIENT REFERRAL; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSIS; PSYCHOTHERAPY; PUBLIC HEALTH; RELAPSE; REVIEW; SCHIZOPHRENIA; STRESS MANAGEMENT;

CLINICAL TRIALS AS TOPIC; HUMANS; PRIMARY PREVENTION; PSYCHOTIC DISORDERS;

EID: 79951559915     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2010.11.012     Document Type: Review

References (40)

1. Eaton W.W. Evidence for universality and uniformity of schizophrenia around the world: assessment and implications. Search for the causes of schizophrenia 1999, vol. IV:21-33. Steinkopf, Darmstadt (Germany). W.F. Gattaz, H. Hafner (Eds.).
2. Rupp A., Keith S.J. The costs of schizophrenia. Psychiatr Clin North Am 1993, 16(2):413-423.
3. Wu E.Q., Birnbaum H.G., Shi L., et al. The economic burden of schizophrenia in the United States. J Clin Psychiatry 2005, 66:1122-1129.
4. Parks J., Svendsen D., Singer P., et al. Morbidity and mortality in people with serious mental illness 2006, National Association of State Mental Health Program Directors, Medical Directors Council, Alexandria (VA).
5. Perkins D.O., Gu H., Boteva K., et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005, 162(10):1785-1804.
6. Lieberman J.A., Perkins D., Belger A., et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001, 50(11):884-897.
7. Haas G.L., Garratt L.S., Sweeney J.A. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res 1998, 32(3-4):151-159.
8. Verdoux H., Liraud F., Bergey C., et al. Is the association between duration of untreated psychosis and outcome confounded ? A two-year follow-up study of first-admitted patients. Schizophr Res 2001, 49(3):231-241.
9. Larsen T., More L., Vibe-Hansen L., et al. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 2000, 45(1-2):1-9.
10. Norman R., Townsend L., Malla A. Duration of untreated psychosis and cognitive functioning in first-episode patients. Br J Psychiatry 2001, 179(4):340-345.
11. Correll C.U., Penzner J.B., Frederickson A.M., et al. Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. Schizophr Bull 2007, 33(3):703-714.
12. Bebbington P., Kuipers L. The predictive utility of expressed emotion in schizophrenia: an aggregate analysis. Psychol Med 1994, 24(3):707-718.
13. Tienari P.A., Wynne L.C., Sorri A., et al. Genotype-environment interaction in schizophrenia-spectrum disorder. Br J Psychiatry 2004, 184:216-222.
14. Yung A.R., Phillips L.J., Yuen H.P., et al. Psychosis prediction: 12-month follow-up of a high-risk (" prodromal" ) group. Schizophr Res 2003, 60:21-32.
15. Miller T.J., McGlashan T.H., Rosen J.L., et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, inter-rater reliability and training to reliability. Schizophr Bull 2003, 29(4):703-715.
16. Klosterkotter J., Hellmich M., Steinmeyer E.M., et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001, 58(2):158-164.
17. Huber G., Gross G., Schuttler R., et al. Longitudinal studies of schizophrenic patients. Schizophr Bull 1980, 6(4):592-605.
18. Cornblatt B., Obuchowski M., Roberts S., et al. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 1999, 11(3):487-508.
19. Haroun N., Dunn L., Haroun A., et al. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull 2005, 32(1):166-178.
20. Yung A.R., Yuen H.P., Berger G.E., et al. Declining transition rates in ultra high risk (prodromal) services: dilution of reduction of risk?. Schizophr Bull 2007, 33(3):673-681.
21. Seidman L.J., Giuliano A.J., Meyer E.C., et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 2010, 67(6):578-588.
22. Sun D., Phillips L., Velakoulis D., et al. Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr Res 2009, 108(1-3):85-92.
23. Kirkbride J.B., Fearon P., Morgan C., et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry 2006, 63(3):250-258.
24. McGorry P., Yung A., Phillips L., et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002, 59(10):921-928.
25. McGlashan T.H., Zipurksy R.B., Perkins D., et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006, 163(5):790-799.
26. Nordentoft M., Thorup A., Petersen L., et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2006, 83(1):29-40.
27. Morrison A.P., French P., Walford L., et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004, 185(4):291-297.
28. Bechdolf A., Wagner M., Veith V., et al. Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv Psychiatry 2007, 1(1):71-78.
29. Amminger G.P., Schafer M.R., Papageorgiou K., et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010, 67(2):146-154.
30. Falloon I.R.H. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 1992, 55(1):4-15.
31. Morrison A.P., French P., Parker S., et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 2007, 33(3):682-687.
32. Rosenbaum B., Valbak K., Harder S., et al. Treatment of patients with first-episode psychosis: two year outcome data from the Danish National Schizophrenia Project. World Psychiatry 2006, 5(2):100-103.
33. McFarlane W.R. Multifamily groups in the treatment of severe psychiatric disorders 2002, Guilford Press, New York.
34. McFarlane W., Stastny P., Deakins S. Family-aided assertive community treatment: a comprehensive rehabilitation and intensive case management approach for persons with schizophrenic disorders. New Dir Ment Health Serv 1992, 53:43-54.
35. McFarlane W.R., Cook W.L., Downing D., et al. Portland identification and early referral: a community-based system for identifying and treating youths at high risk of psychosis. Psychiatr Serv 2010, 61(5):512-515.
36. McFarlane W.R. Family-based treatment in prodromal and first-episode psychosis. Early intervention in psychotic disorders 2001, 197-230. Kluwer Academic Publishers, Amsterdam. T. Miller (Ed.).
37. Addington J., Cadenhead K., Cannon T.D., et al. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull 2007, 33(3):665-672.
38. Cannon T.D., Cadenhead K., Cornblatt B., et al. Prediction of psychosis in youth at high clinical risk. Arch Gen Psychiatry 2008, 65(1):28-37.
39. Cornblatt B.A., Lencz T., Smith C.W., et al. Can antidepressants be used to treat the schizophrenia prodrome. Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007, 68:546-557.
40. McGurk S.R., Mueser K.T., Pascaris A. Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial. Schizophr Bull 2005, 31(4):898-909.